Vipadenant
Vipadenant is a pharmaceutical compound that was investigated for its potential use as a treatment for Parkinson's disease. It acts as an antagonist of the adenosine A2A receptor, which is a target of interest in the management of Parkinsonian symptoms.
Mechanism of Action[edit | edit source]
Vipadenant functions by selectively blocking the adenosine A2A receptors. These receptors are predominantly found in the basal ganglia, a region of the brain that is critically involved in the regulation of movement. In Parkinson's disease, the dopaminergic neurons in the basal ganglia are degenerated, leading to an imbalance in neurotransmitter activity. By inhibiting the A2A receptors, vipadenant helps to restore this balance, potentially improving motor function and reducing symptoms such as tremors and rigidity.
Clinical Development[edit | edit source]
Vipadenant was developed by Biogen Idec and underwent several phases of clinical trials. Initial studies showed promise in improving motor symptoms in patients with Parkinson's disease. However, further development was halted due to concerns about safety and efficacy. The compound was found to have potential side effects that outweighed its benefits in the target population.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of vipadenant includes its absorption, distribution, metabolism, and excretion. Vipadenant is orally bioavailable, meaning it can be administered in pill form. It is metabolized in the liver and excreted primarily through the kidneys. The half-life of vipadenant allows for once-daily dosing, which is convenient for patients.
Research and Future Directions[edit | edit source]
Although vipadenant is no longer in active development, research into adenosine A2A receptor antagonists continues. These compounds remain a promising avenue for the treatment of Parkinson's disease and other neurological disorders. Future studies may focus on improving the safety profile of these drugs or combining them with other therapies to enhance their efficacy.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
